Answers are grounded in this paper and cite their sources.
Case reports demonstrate diagnostic complexities of remimazolam anaphylaxis in patients with varying conditions, suggesting thorough evaluations are crucial.
Background: Reports of remimazolam formulation-associated anaphylaxis are increasing as its use expands. Between 2023 and 2025, we identified two severe reactions among 1,592 patients who received remimazolam at our institution. Case: A 65-year-old man (American Society of Anesthesiologists physical status [ASA PS] III) with end-stage renal disease developed profound hypotension without cutaneous signs after induction with 10 mg of remimazolam and peri-induction cefazedone administration. Surgery was cancelled due to persistent hypotension. Serum tryptase measured 6 h after the event was 38.0 μg/L; however, delayed skin testing was negative. Subsequent propofol-based anesthesia without cefazedone re-administration was uneventful. A 50-year-old woman (ASA PS I) developed hypotension and facial flushing within 2 min of receiving 10 mg of remimazolam. Although serum tryptase levels remained within the normal range (5.3 and 5.1 μg/L), delayed skin testing for remimazolam was positive. Conclusions: Diagnosis of remimazolam formulation-associated hypersensitivity may remain inconclusive when based on a single diagnostic test. Accurate evaluation requires integrating timed tryptase, delayed skin testing, and careful evaluation of exposure history.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: